Evaluation of EGFR, KRAS and BRAF gene mutations in renal cell carcinoma

A subset of renal cell carcinoma (RCC) patients has been shown to respond to anti-EGFR therapy. As KRAS and BRAF mutations are associated with poor response to anti-EGFR therapy in some cancers, it has been suggested that screening for KRAS and BRAF mutations in RCC may be a promising strategy to id...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Kidney Cancer VHL
Hauptverfasser: Bayrak, Omer, Sen, Haluk, Bulut, Ersan, Cengiz, Beyhan, Karakok, Metin, Erturhan, Sakip, Seckiner, Ilker
Format: Artigo
Sprache:Inglês
Veröffentlicht: Codon Publications 2014
Schlagworte:
Short Communication
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5345528/
https://ncbi.nlm.nih.gov/pubmed/28326248
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15586/jkcvhl.2014.10
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge